Friday, October 26, 2012
The FDA published fee notices by the Generic Drug User Fee Amendments of 2012, establishing fee amounts and due dates for applications pending on Oct. 1, which are considered backlog applications, and for new generic drug submissions received as of Oct. 1.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.